OMNISENSE 7000/8000SSunlight Omnisense™ 7000S--
Enter the Sunlight Omnisense 7000S bone sonometer--so accurate and economical, it's poised to become the new standard in bone strength assessment. Sunlight's patented Omnipath technology takes the Omnisense 7000S beyond the one-time snapshot. Its low cost allows you to offer and perform in-office measurements more frequently with just a one-minute pass over the wrist--developing a profile that flags osteoporotic development early on. Finally, a way to meet the burgeoning demand for a complete bone assessment solution cost-effectively, with no compromise in accuracy or precision. It's about time. Diagnose and monitor osteoporosis
At Last: Diagnose and Monitor Osteoporosis at the Point of Care Sunlight's Omnisense7000S bone sonometer is an office-based solution so accurate, it has an FDA approved claim for monitoring bone changes over time. The technician simply scans the patient's wrist and, in minutes, generates a comprehensive picture of fracture risk. The Omnisense 7000S uses a patented axial transmission form of quantitative ultrasound we call Omnipath. Instead of relying on x-rays, Omnipath measures the velocity of ultrasonic waves (speed of sound) that propagate axially along the distal 1/3 radius. The resulting output considers multiple bone strength properties such as bone mineral density (BMD), elasticity, cortical thickness, and micro-architecture--without soft-tissue-related inaccuracies so typical with other testing devices. The system uses World Health Organization (WHO) criteria in assessing fracture risk and user- friendly software allows you to store comprehensive patient information. This scalable platform includes a record management database and patient scheduling system. Sample of Common lCD-9 Codes for Bone Densitometry*
Reimbursement Information Bone Mass Measurement Rule: rule for coverage and payment of bone mass measurements as published in The Federal Register Volume 63 November 121/Wednesday, June 24, 1998, states that bone strength assessment with an FDA-approved bone sonometer is reimbursable. Reimbursement: Medicare reimbursement ultrasound testing is covered under CPT code 76977. HCFA/Medicare 2001 national average is approximately $58 per study. Most insurance companies reimburse for Ultrasonometry studies. Conditions for Coverage: A woman determined by the physician to be estrogen deficient and at clinical risk for osteoporosis, based on medical history and other findings. An individual with vertebral
abnormalities as demonstrated
by an x-ray indicating
osteoporosis, osteopenia, or An individual receiving or expecting to receive glucocorticoid steroid therapy. An individual with primary hyperparathyroidism. An individual being monitored to assess response to or efficacy of an FDA-approved osteoporosis drug therapy. Repetitive Testing: Medicare may cover repetitive testing after 23 months of last test, more frequently if medically necessary. *Medicare reimbursement rates vary by region. Please check your local carrier for exact amount and guidelines for filing of claims. |
|
Message from the MEC/OBD
president:"As president, I have committed my company to providing medical facilities with "state-of-the-art" bone densitometry equipment to help them do a better job with preventing, testing for, screening for, detecting, diagnosing, and treating Osteoporosis which ravage so many women and men. Our diagnostic equipment will speed up the prevention, detection, diagnosis, and treatment of Osteoporosis and osteoporotic bone disorders in men and women. The key to preventing Osteoporosis in women and men is early detection, diagnosis, and treatment. This means measuring, testing, screening, detecting, and diagnosing low bone mass in women and men early in their lifetimes so that effective treatment can stop the Osteoporosis dead in its tracks." Together, we can help protect families from this terrible disease. Sincerely, |
MEC/OBD websites are managed by Online Design & Technology in accordance with MEC/OBD & Technology agreement #053198.